EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Topical Losartan in the Management of Corneal Scarring Fibrosis: Update on Dosage, Efficacy, and Potential Epithelial Toxicity

Barbara A L Dutra, Steven E Wilson

Journal of Ocular Pharmacology and Therapeutics · 01.06.2025 · 41 (5) · 232-236

DOI: 10.1089/jop.2024.0200 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Ocular Pharmacology and Therapeutics, online erschienen am 02.06.2025. Verfasst von Barbara A L Dutra und 1 weiteren Autor:innen. Beteiligte Einrichtung: The Cole Eye Institute, The Cleveland Clinic, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Losartan, Cicatrix, Angiotensin II Type 1 Receptor Blockers, Epithelium, Corneal. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Losartan is an angiotensin II receptor blocker (ARB) that also inhibits transforming growth factor (TGF)-beta signaling by blocking the activation of extracellular signal-regulated kinase (ERK) in the noncanonical TGF-beta signaling pathway. Rabbit studies demonstrated the efficacy of topical losartan in reducing fibrotic scarring following a variety of corneal injuries, such as descemetorhexis, alkali burns, and photorefractive keratectomy (PRK). Several human case reports have subsequently shown the efficacy of topical losartan in treating scarring fibrosis resulting from surgical complications and infections. Since rabbit studies have also found concentration-dependent corneal epithelial toxicity associated with topical losartan, a lower concentration of 0.2 mg/mL administered 6 times daily is recommended in corneas with epithelial defects until epithelial closure is achieved before using standard 0.8 mg/mL losartan 6 times a day for the duration of treatment. For eyes with intact epithelium, a dose of 0.8 mg/mL 6 times daily is recommended throughout the treatment period. Doses of topical losartan above 0.8 mg/mL should be avoided due to dosage-related increases in persistent epithelial defects. Clinical studies are needed to further assess questions such as which corneal fibrotic disorders are most likely to respond to topical losartan treatment and whether a lower frequency of application leads to greater treatment failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LosartanCicatrixAngiotensin II Type 1 Receptor BlockersEpithelium, CornealCorneal DiseasesCorneaHumansAnimalsFibrosisAdministration, TopicalRabbitsDose-Response Relationship, DrugOphthalmic SolutionsCorneal Injuries

Stichwörter der Autor:innen

TGF betacorneaepithelial toxicitylosartanscarringwound healing

Substanzen

LosartanAngiotensin II Type 1 Receptor BlockersOphthalmic Solutions

Autor:innen und Institutionen

  • The Cole Eye Institute, The Cleveland Clinic, Cleveland, Ohio, USA.
  • Department of Ophthalmology, University of Sao Paulo, Sao Paulo, Brazil.

Zitieren

APA

Dutra, B. A. L., & Wilson, S. E. (2025). Topical Losartan in the Management of Corneal Scarring Fibrosis: Update on Dosage, Efficacy, and Potential Epithelial Toxicity. Journal of Ocular Pharmacology and Therapeutics, 41(5), 232-236. https://doi.org/10.1089/jop.2024.0200

Vancouver

Dutra BAL, Wilson SE. Topical Losartan in the Management of Corneal Scarring Fibrosis: Update on Dosage, Efficacy, and Potential Epithelial Toxicity. Journal of Ocular Pharmacology and Therapeutics. 2025;41(5):232-236. doi:10.1089/jop.2024.0200

BibTeX
@article{Dutra2025,
  author = {Dutra, Barbara A L and Wilson, Steven E},
  title = {Topical Losartan in the Management of Corneal Scarring Fibrosis: Update on Dosage, Efficacy, and Potential Epithelial Toxicity},
  journal = {Journal of Ocular Pharmacology and Therapeutics},
  year = {2025},
  volume = {41},
  number = {5},
  pages = {232--236},
  doi = {10.1089/jop.2024.0200}
}
Kostenlos starten →